Evidence map›Paper›PMID 35795925›Full record

ArticleThe British journal of psychiatry : the journal of mental science2022

Time to re-evaluate the risks and benefits of valproate and a call for action.

Oliver D Howes, Thomas R E Barnes, Belinda R Lennox, Sarah Markham, Sridhar Natesan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of psychiatry : the journal of mental science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Oliver D HowesPsychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; and Faculty of Medicine, Institute of Clinical Sciences, Imperial College London, UK.
Thomas R E BarnesFaculty of Medicine, Department of Brain Sciences, Imperial College London, UK.ORCID 0000-0002-2324-656X
Belinda R LennoxDepartment of Psychiatry, University of Oxford, UK.ORCID 0000-0002-4972-8786
Sarah MarkhamDepartment of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.ORCID 0000-0002-8755-5935
Sridhar NatesanPsychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; and Faculty of Medicine, Institute of Clinical Sciences, Imperial College London, UK.ORCID 0000-0001-7499-1714

Funding

Department of Health IS-BRC-1215-20018Health Technology Assessment Programme NIHR127755Medical Research Council MC_U120097115Medical Research Council MR/N027078/1
6 · The paper itself

Abstract

Valproate is widely used in psychiatry and neurology, including off-label use. Here we consider its potential benefits and risks, particularly for women of childbearing potential, and the evidence that clinical guidelines are adhered to. Finally, we consider the implications for clinical practice and research into its efficacy in off-label indications.

Indexed as

AnticonvulsantsValproic AcidFemaleHumansRisk AssessmentAnticonvulsantsValproic Acidanticonvulsantsdrug interactions and side-effectseducation and trainingpolypharmacypsychotic disorders

Identifiers

PMID35795925
PMCPMC7613842

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.